Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
Clinical trial NCT05203003 · RECRUITING
Trial details
- NCT number
- NCT05203003
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2022-04-22
- Primary completion
- 2027-04-01
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.